This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Velickovic, M. Articles by Grebe, S. K. G. Search for Related Content PubMed PubMed Citation Articles by Velickovic, M. Articles by Grebe, S. K. G.

Loss of Heterozygosity at 3p14.2 in Clear Cell Renal Cell Carcinoma Is an Early Event and Is Highly Localized to the FHIT Gene Locus¹

Department of Pathology, Wellington School of Medicine, Wellington, New Zealand

ABSTRACT

The VHL tumor suppressor gene (TSG) at 3p25–26 is strongly implicated in the pathogenesis of clear cell renal cell carcinoma (cRCC). In addition, 3p14.2 and 3p21 are suspected of harboring additional TSGs in cRCC, with FHIT being a candidate TSG at 3p14.2. We examined 87 microdissected, histologically well-defined cRCCs classified according to tumor-node-metastasis (TNM) stage (stage 1, 23 cases; stage 2, 14 cases; stage 3, 24 cases; stage 4, 26 cases) and Fuhrman grade (grade 1, 24 cases; grade 2, 19 cases; grade 3, 19 cases; grade 4, 8 cases; sarcomatoid cRCC, 17 cases) for loss of heterozygosity (LOH) at 3p14.2 and 3p25–26 using a series of precisely mapped microsatellite probes. We found that LOH at 3p14.2 exceeded LOH at 3p25–26 in frequency (69% versus 48.3%; P < 0.03) and was highly localized to markers within the FHIT gene locus (D3S1300 and D3S4260), with the majority of chromosomal breakpoints also mapping to this region. In addition, 3p14.2 LOH (P < 0.03), but not 3p25–26 LOH (P = nonsignificant), was associated with lower tumor grades (grades 1–3). These findings suggest that 3p14.2 genomic deletions may be among the earliest events in cRCC pathogenesis, preceding genomic deletions at the VHL locus. FHIT, or an as yet undiscovered TSG mapping to the D3S4103–D3S4260 interval, could be the molecular target of the 3p14.2 deletions.

This article has been cited by other articles:

				P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]

				P. Schraml, A. Hergovitz, F. Hatz, M. B. Amin, S. D. Lim, W. Krek, M. J. Mihatsch, and H. Moch Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression Am. J. Pathol., September 1, 2003; 163(3): 1013 - 1020. [Abstract] [Full Text] [PDF]

				F. Sukosd, N. Kuroda, T. Beothe, A. P. Kaur, and G. Kovacs Deletion of Chromosome 3p14.2-p25 Involving the VHL and FHIT Genes in Conventional Renal Cell Carcinoma Cancer Res., January 15, 2003; 63(2): 455 - 457. [Abstract] [Full Text] [PDF]

				Y. Kamiya, M. Puzianowska-Kuznicka, P. McPhie, J. Nauman, S.-y. Cheng, and A. Nauman Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma Carcinogenesis, January 1, 2002; 23(1): 25 - 33. [Abstract] [Full Text] [PDF]

				C. Morrissey, A. Martinez, M. Zatyka, A. Agathanggelou, S. Honorio, D. Astuti, N. V. Morgan, H. Moch, F. M. Richards, T. Kishida, et al. Epigenetic Inactivation of the RASSF1A 3p21.3 Tumor Suppressor Gene in Both Clear Cell and Papillary Renal Cell Carcinoma Cancer Res., October 1, 2001; 61(19): 7277 - 7281. [Abstract] [Full Text] [PDF]

				A. J. W. Paige, K. J. Taylor, C. Taylor, S. G. Hillier, S. Farrington, D. Scott, D. J. Porteous, J. F. Smyth, H. Gabra, and J. E. V. Watson WWOX: A candidate tumor suppressor gene involved in multiple tumor types PNAS, September 25, 2001; 98(20): 11417 - 11422. [Abstract] [Full Text] [PDF]

				M. Velickovic, B. Delahunt, S. Storkel, and S. K. G. Grebem VHL and FHIT Locus Loss of Heterozygosity Is Common in All Renal Cancer Morphotypes But Differs in Pattern and Prognostic Significance Cancer Res., June 1, 2001; 61(12): 4815 - 4819. [Abstract] [Full Text] [PDF]

				N. S. Werner, Z. Siprashvili, L. Y. Y. Fong, G. Marquitan, J. K. Schroder, W. Bardenheuer, S. Seeber, K. Huebner, J. Schutte, and B. Opalka Differential Susceptibility of Renal Carcinoma Cell Lines to Tumor Suppression by Exogenous Fhit Expression Cancer Res., June 1, 2000; 60(11): 2780 - 2785. [Abstract] [Full Text]